Nachrichten zur Hims & Hers Health Inc. Aktie

Hims’ Upbeat Forecast Depends on Continued Copycat Weight-Loss Drug Sales

Hims & Hers Health Inc. forecast 2026 revenue that met Wall Street’s expectations, provided that it can continue selling copycat…

Hims & Hers, the telehealth provider best known for its compounded weight-loss drugs, issues a weak outlook.…

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 7 Oversold Pharma Stocks to Buy Now. Hims & Hers Health,…

Feb 23 (Reuters) - Hims & Hers Health forecast 2026 revenue above estimates on Monday, betting on increased sales for…

Feb 23 (Reuters) - Hims & Hers Health forecast 2026 revenue above estimates on Monday, betting on increased sales for…

Hims & Hers Health forecast 2026 revenue above estimates on Monday, betting on increased sales for its personalized healthcare offerings.…

A class of GLP-1 patients claim that telehealth company Hims & Hers falsely advertised its compounded injections as made with…

@media (max-width: 768px) { .image-container…

Novo Nordisk has filed a lawsuit against Hims & Hers Health (NYSE:HIMS) over alleged patent infringement tied to compounded weight…

Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million…

When you put people at the center of health, more people want to engage. Here’s how we’re thinking about last…